China Pushes For Lower Sovaldi Prices Amid Rising HCV Cases
This article was originally published in PharmAsia News
Executive Summary
Excluded from an access program targeting low-income countries, China is now working to secure lower prices for hepatitis C drug Sovaldi via negotiations with manufacturer Gilead Sciences, hoping to bring the highly effective therapy to the country early, local health officials have disclosed.